10.07.26 -- What The Data Says About Europe's CDMO Advantage

Platform biotech companies face critical choices on partnering, licensing, or selling technology—decisions that shape focus, valuation, and long‑term success beyond scientific innovation alone.

Learn how early QC integration, proactive analytical risk management, and cross-functional collaboration can improve readiness, reduce surprises, and strengthen release testing predictability

Here, we demonstrate how adding small amounts of SYLOID® mesoporous silica to Cholesterol before jet milling can enhance processing efficiency, boost yield, and improve micronization performance.

Optimizing L-Leucine balances porosity and surface enrichment in spray-dried formulations. Precise adjustments alter particle structure to enhance aerodynamic performance and lung deposition.

Successful drug development and manufacturing rely on strong communication. Early collaboration and active listening help teams reduce risk, align expectations, and solve challenges.

Late-phase OSD scale-up demands more than technical know-how. Examine the frameworks, tools, and partnership models that determine whether promising molecules reach commercial production reliably.

Decisions made during clinical manufacturing have lasting consequences at commercial scale. View how fill/finish equipment choices shape long-term flexibility, throughput, and operational continuity.

Inhaled biologics are advancing as better formulations, particle design, and devices enable targeted delivery. Tracking key trends helps teams manage complexity and advance future therapies.